鼻咽癌的免疫治疗研究进展

doi:10.11904/j.issn.1002-3070.2021.06.011

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (6): 542-546.doi: 10.11904/j.issn.1002-3070.2021.06.011

鼻咽癌的免疫治疗研究进展

杨开炎^1,2, 韦永昌², 杨秋云² 综述, 唐凤珠³ 审校

1.广西中医药大学瑞康临床医学院(南宁 530000);
2.广西百色市人民医院耳鼻咽喉头颈外科;
3.广西壮族自治区人民医院耳鼻咽喉头颈外科

收稿日期:2020-12-29 修回日期:2021-02-04 出版日期:2021-12-28 发布日期:2021-12-17
通讯作者: 杨开炎,E-mail:19447620@qq.com
作者简介:杨开炎,男,(1980-),硕士,副主任医师,从事头颈肿瘤的研究。
基金资助:
百色市科技计划项目(编号:百科计20161501)

Research progress in immunotherapy of nasopharyngeal carcinoma

YANG Kaiyan^1,2, WEI Yongchang², YANG Qiuyun², TANG Fengzhu³

1. Ruikang Clinical Faculty of Guangxi University of Chinese Medicine,Nanning 530000,China;
2. Department of Otorhinolaryngology,Head and Neck Surgery,People′s Hospital of Guangxi Baise;
3. Department of Otorhinolaryngology Head and Neck Surgery,People′s Hospital of Guangxi Zhuang Autonomous Region

Received:2020-12-29 Revised:2021-02-04 Online:2021-12-28 Published:2021-12-17

摘要/Abstract

摘要： 鼻咽癌是中国南方地区发病率较高的恶性肿瘤,鼻咽癌的治疗目前以同步放化疗为主要治疗方式,早期鼻咽癌的预后较好,而晚期鼻咽癌的预后较差。免疫治疗作为一种治疗恶性肿瘤的新方法,在临床上应用越来越广泛,并在一些恶性肿瘤的治疗上取得较好效果,成为目前临床研究热点。本文对免疫治疗应用在鼻咽癌方面的研究进行综述,以发现存在的问题和新的研究方向。

关键词: 鼻咽癌, 免疫疗法, 细胞免疫治疗, 单克隆抗体, 肿瘤疫苗

Abstract: Nasopharyngeal carcinoma is a malignant tumor with a high incidence in southern China.The treatment of nasopharyngeal carcinoma currently uses concurrent radiotherapy and chemotherapy as the main treatment.The prognosis of early nasopharyngeal carcinoma is better,while the prognosis of advanced nasopharyngeal carcinoma is poor.As a new method of treating malignant tumors,immunotherapy is more and more widely used clinically.It has achieved good results in the treatment for some malignant tumors,and has become a current clinical research hotspot.This article reviews the application of immunotherapy in nasopharyngeal carcinoma in order to discover existing problems and new research directions.

Key words: Nasopharyngeal carcinoma, Immunotherapy, Cellular immunotherapy, Monoclonal antibody, Tumor vaccines

中图分类号:

R739.6

杨开炎, 韦永昌, 杨秋云, 唐凤珠. 鼻咽癌的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 542-546.

YANG Kaiyan, WEI Yongchang, YANG Qiuyun, TANG Fengzhu. Research progress in immunotherapy of nasopharyngeal carcinoma[J]. Journal of Practical Oncology, 2021, 35(6): 542-546.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.06.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I6/542

参考文献

1 Cao SM,Simons MJ,Qian CN.The prevalence and prevention of nasopharyngeal carcinoma in China[J].Chin J Cancer,2011,30(2):114-119.
2 卢江岳,张建鑫,葛晓峰.鼻咽癌同步推量同步放化疗与常规分割后缩野同步放化疗的疗效及毒性反应对比分析[J].实用肿瘤学杂志,2020,34(5):440-445.
3 Wu CC,Fang CY,Hsu HY,et al.EBV reactivation as a target of luteolin to repress NPC tumorigenesis[J].Oncotarget,2016,7(14):18999-19017.
4 Le QT,Colevas AD,O′Sullivan B,et al.Current treatment landscape of nasopharyngeal carcinoma and potential trials evaluating the value of immunotherapy[J].J Natl Cancer Inst,2019,111(7):655-663.
5 Ma SX,Zhou T,Huang Y,et al.The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma:a systematic review and meta-analysis[J].Ann Transl Med,2018,6(11):201.
6 Eggermont A,Blank CU,Mandala M,et al.Adjuvant pembrolizumab versus placebo in resected stage III melanoma[J].N Engl J Med,2018,378(19):1789-1801.
7 Gandhi L,Rodríguez-Abreu D,Gadgeel S,et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J].N Engl J Med,2018,378(22):2078-2092.
8 Motzer RJ,Penkov K,Haanen J,et al.Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J].N Engl J Med,2019,380(12):1103-1115.
9 Burtness B,Harrington KJ,Greil R,et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048):a randomised,open-label,phase 3 study[J].Lancet,2019,394(10212):1915-1928.
10 Holstein SA,Lunning MA.CAR T-cell therapy in hematologic malignancies:a voyage in progress[J].Clin Pharmacol Ther,2020,107(1):112-122.
11 Verdoodt F,Dehlendorff C,Kjaer SK.Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia:a danish nationwide cohort study[J].Clin Infect Dis,2020,70(4):608-614.
12 Stelow EB,Wenig BM.Update From The 4th edition of the World Health Organization classification of head and neck tumours:Nasopharynx[J].Head Neck Pathol,2017,11(1):16-22.
13 Jiang L,Xie C,Lung HL,et al.EBNA1-targeted inhibitors:novel approaches for the treatment of Epstein-Barr virus-associated cancers[J].Theranostics,2018,8(19):5307-5319.
14 Turrini R,Merlo A,Martorelli D,et al.A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors[J].Oncoimmunology,2017,6(4):e1304338.
15 Jain A,Chia WK,Toh HC.Immunotherapy for nasopharyngeal cancer-a review[J].Chin Clin Oncol,2016,5(2):22.
16 Taylor GS,Long HM,Brooks JM,et al.The immunology of Epstein-Barr virus-induced disease[J].Annu Rev Immunol,2015,33:787-821.
17 Fu T,Voo KS,Wang RF.Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo[J].J Clin Invest,2004,114(4):542-550.
18 Gourzones C,Barjon C,Busson P.Host-tumor interactions in nasopharyngeal carcinomas[J].Semin Cancer Biol,2012,22(2):127-136.
19 Chen Y,Chen RJ,Huang XC,et al.Construction of latent membrane protein 2A chimeric antigen receptor-T cells and their lethal effects on nasopharyngeal carcinoma cells[J].Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,2018,53(12):925-930.
20 Guo X,Zheng H,Luo W,et al.5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells[J].Sci Rep,2017,7(1):4859.
21 Huang J,Fogg M,Wirth LJ,et al.Epstein-Barr virus-specific adoptive immunotherapy for recurrent,metastatic nasopharyngeal carcinoma[J].Cancer,2017,123(14):2642-2650.
22 Brown CE,Mackall CL.CAR T cell therapy:inroads to response and resistance[J].Nat Rev Immunol,2019,19(2):73-74.
23 Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
24 Larbcharoensub N,Mahaprom K,Jiarpinitnun C,et al.Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in Epstein-Barr virus-associated nasopharyngeal carcinoma[J].Am J Clin Oncol,2018,41(12):1204-1210.
25 Jiang F,Yu W,Zeng F,et al.PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma[J].BMC Cancer,2019,19(1):503.
26 Huang PY,Guo SS,Zhang Y,et al.Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma[J].Oncotarget,2016,7(11):13060-13068.
27 Wang YQ,Zhang Y,Jiang W,et al.Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis[J].J Immunother Cancer,2019,7(1):298.
28 Ma B,Lim WT,Goh BC,et al.Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma:an international,multicenter study of the mayo clinic phase 2 consortium(NCI-9742)[J].J Clin Oncol,2018,36(14):1412-1418.
29 Fang W,Yang Y,Ma Y,et al.Camrelizumab(SHR-1210)alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma:results from two single-arm,phase 1 trials[J].Lancet Oncol,2018,19(10):1338-1350.
30 Wu K,Yi M,Qin S,et al.The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors:a meta-analysis[J].Exp Hematol Oncol,2019,8:26.
31 Zhou S,Khanal S,Zhang H.Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients[J].Ther Clin Risk Manag,2019,15:211-221.
32 Dasari V,Sinha D,Neller MA,et al.Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases:emerging strategies for clinical development[J].Expert Rev Vaccines,2019,18(5):457-474.
33 Taylor GS,Steven NM.Therapeutic vaccination strategies to treat nasopharyngeal carcinoma[J].Chin Clin Oncol,2016,5(2):23.
34 Lin CL,Lo WF,Lee TH,et al.Immunization with Epstein-Barr virus(EBV)peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma[J].Cancer Res,2002,62(23):6952-6958.
35 Si Y,Deng Z,Lan G,et al.The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients:a phase I clinical trial and two-year follow-up[J].Chem Pharm Bull(Tokyo),2016,64(8):1118-1123.
36 Taylor GS,Jia H,Harrington K,et al.A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr virus(EBV)target antigens:a phase I trial in UK patients with EBV-positive cancer[J].Clin Cancer Res,2014,20(19):5009-5022.
37 Wojtak K,Perales-Puchalt A,Weiner DB.Novel synthetic DNA immunogens targeting latent expressed antigens of Epstein-Barr virus elicit potent cellular responses and inhibit tumor growth[J].Vaccines(Basel),2019,7(2):44.
38 Kalra M,Gerdemann U,Luu JD,et al.Epstein-Barr virus(EBV)-derived BARF1 encodes CD4-and CD8-restricted epitopes as targets for T-cell immunotherapy[J].Cytotherapy,2019,21(2):212-223.
39 Ahmed M,Lopez-Albaitero A,Pankov D,et al.TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies[J].JCI Insight,2018,3(4):e97805.

[1]	张伟明, 孙坚萍, 赵艳. 共刺激受体:肿瘤免疫疗法的潜在靶点[J]. 实用肿瘤学杂志, 2021, 35(5): 441-446.
[2]	吴哲, 庞亚, 明智, 刘可, 王东, 晏军. 人工智能技术在鼻咽癌放疗危及器官自动勾画中的应用研究[J]. 实用肿瘤学杂志, 2021, 35(2): 137-141.
[3]	李佳星,曹辉,张瑜,李勇,王姿,景楚滢,黄立敏. 二代测序检测上行型与下行型鼻咽癌中高频突变基因的研究[J]. 实用肿瘤学杂志, 2021, 35(1): 28-34.
[4]	卢江岳, 张建鑫, 葛晓峰. 鼻咽癌同步推量同步放化疗与常规分割后缩野同步放化疗的疗效及毒性反应对比分析[J]. 实用肿瘤学杂志, 2020, 34(5): 440-445.
[5]	林映羲, 龙雅怡, 傅俊宏, 刘芳, 陈敏敏. 单核/巨噬细胞在非霍奇金淋巴瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 352-356.
[6]	谢艺才, 高健全. 动态增强MRI成像在鼻咽癌诊疗中的应用价值[J]. 实用肿瘤学杂志, 2020, 34(3): 258-261.
[7]	阮鹏, 谭爱丽. 血清中microRNA-127对鼻咽癌患者化疗抗性的预测价值[J]. 实用肿瘤学杂志, 2019, 33(6): 508-512.
[8]	刘耿淳, 申良方. 血清长链非编码RNA MALAT1和AFAP1-AS1与鼻咽癌临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 513-518.
[9]	陈光浩, 方靖萱, 彭素娟, 严炜薇, 王福海, 陈承哲, 陈泗川, 潘建基, 邱素芳. PNCK对鼻咽癌细胞增殖和凋亡作用的研究[J]. 实用肿瘤学杂志, 2019, 33(5): 397-401.
[10]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[11]	张攀, 张迪综述, 戴晓波审校. 复发鼻咽癌再程放射治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 92-96.
[12]	李丹，王勇. 微创外科治疗联合药物对局限性鼻咽癌微小浸润灶的近远期疗效分析[J]. 实用肿瘤学杂志, 2017, 31(3): 234-237.
[13]	黄娟娟, 王雯欣综述, 曹峰林审校. 血液系统恶性肿瘤细胞免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 61-65.
[14]	李书桢, 杨云利. 鼻咽癌侵犯鼻窦的研究进展[J]. 实用肿瘤学杂志, 2015, 29(6): 573-576.
[15]	李汝懿综述, 陆建波审校. 基因表达谱在肿瘤病理诊断与鉴别诊断中的意义[J]. 实用肿瘤学杂志, 2015, 29(3): 275-278.

鼻咽癌的免疫治疗研究进展

Research progress in immunotherapy of nasopharyngeal carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价